GLP-1 ClassGLP-3R
GLP-3R is a triple-receptor agonist (GIP / GLP-1 / glucagon) currently in Phase 2/3 clinical trials for obesity and type 2 diabetes, developed by Eli Lilly. It has demonstrated up to ~24% body weight reduction at 48 weeks in the highest dose groups — surpassing earlier dual-agonist drugs like tirzepatide.

